SEIPIN Regulates Lipid Droplet Expansion and Adipocyte Development by Modulating the Activity of Glycerol-3-phosphate Acyltransferase

0301 basic medicine lipodystrophy 1300 Biochemistry 572 QH301-705.5 lipid droplets 610 Genetics and Molecular Biology Saccharomyces cerevisiae yeast 3101 Biochemistry and Cell Biology Article SEIPIN adipogenesis Mice 03 medical and health sciences proteomics GPAT3 GPAT4 3T3-L1 Cells GTP-Binding Protein gamma Subunits 616 Adipocytes 2.1 Biological and endogenous factors Animals Humans anzsrc-for: 31 Biological Sciences Biology (General) Enzyme Inhibitors Mammals 0303 health sciences Adipogenesis anzsrc-for: 3101 Biochemistry and Cell Biology Lipid Droplets 1-Acylglycerol-3-Phosphate O-Acyltransferase Heterotrimeric GTP-Binding Proteins AGPAT2 phosphatidic acid Kinetics BSCL seipin BSCL1 BSCL2 Drosophila 31 Biological Sciences Protein Binding
DOI: 10.1016/j.celrep.2016.10.037 Publication Date: 2016-11-01T16:30:55Z
ABSTRACT
Berardinelli-Seip congenital lipodystrophy 2 (BSCL2) is caused by loss-of-function mutations in SEIPIN, a protein implicated in both adipogenesis and lipid droplet expansion but whose molecular function remains obscure. Here, we identify physical and functional interactions between SEIPIN and microsomal isoforms of glycerol-3-phosphate acyltransferase (GPAT) in multiple organisms. Compared to controls, GPAT activity was elevated in SEIPIN-deficient cells and tissues and GPAT kinetic values were altered. Increased GPAT activity appears to underpin the block in adipogenesis and abnormal lipid droplet morphology associated with SEIPIN loss. Overexpression of Gpat3 blocked adipogenesis, and Gpat3 knockdown in SEIPIN-deficient preadipocytes partially restored differentiation. GPAT overexpression in yeast, preadipocytes, and fly salivary glands also formed supersized lipid droplets. Finally, pharmacological inhibition of GPAT in Seipin-/- mouse preadipocytes partially restored adipogenesis. These data identify SEIPIN as an evolutionarily conserved regulator of microsomal GPAT and suggest that GPAT inhibitors might be useful for the treatment of human BSCL2 patients.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (52)
CITATIONS (148)